German China
Search

USA: New Therapies for Cancer Patients Symphogen to Use Thermo Fisher's Mass Spectrometry Technology to Analyze Complex Therapeutic Proteins

| Editor: Alexander Stark

Thermo Fisher Scientific and Symphogen, a clinical-stage antibody oncology-focused company, have entered into a two-year collaborative partnership to deliver validated, platform workflows for simplified characterization and quality monitoring of complex therapeutic proteins.

Related Company

Symphogen will use the Thermo Scientific Q Exactive Plus Orbitrap liquid chromatography-tandem mass spectrometry (LC-MS/MS) system with Bio Pharma option.
Symphogen will use the Thermo Scientific Q Exactive Plus Orbitrap liquid chromatography-tandem mass spectrometry (LC-MS/MS) system with Bio Pharma option.
(Source: Thermo Fisher Scientific)

Sunnyvale/USA — Building on a decade-long relationship, the new collaboration will develop protein analysis workflows to accelerate drug development for biopharmaceutical innovators, biosimilar manufacturers, contract research organizations, and contract development and manufacturing organizations.

The client will use the Q Exactive Plus Orbitrap liquid chromatography-tandem mass spectrometry (LC-MS/MS) system with Bio Pharma Option to create, test and validate platform workflows for intact and native mass analysis of therapeutic monoclonal antibody (mAb) mixtures. Additional focus will be placed on the development of automated multi-attribute method (MAM) workflows for monitoring critical quality attributes of proteins using high-resolution accurate-mass mass spectrometry in a quality control environment.

John Rontree, senior director pharma & biopharma, chromatography and mass spectrometry, Thermo Fisher Scientific, said that the growing demand for more targeted and personalized treatment modalities resulted in the development of increasingly complex drug products, requiring research and development of advanced workflows to monitor their structure, manufacturing variation and quality. The collaboration would enable the companies to jointly leverage their established mass spectrometry technology to develop and implement novel, easy-to-use analytical strategies for complex mAb mixtures needed by drug manufacturers to drive the development of new therapies for cancer patients.

(ID:45595580)